Last reviewed · How we verify

NCT05714163

Effects of Ai Chi on Scapular Muscle Activation in Overhead Athletes With Scapular Dyskinesis

Completed Last updated 15 January 2026
What this trial tests

trial in Scapular Dyskinesis in 21 participants. Completed in 23 February 2023.

Timeline
16 October 2022
Primary endpoint
23 February 2023
23 February 2023

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment21
Start date16 October 2022
Primary completion23 February 2023
Estimated completion23 February 2023
Sites1 location across Taiwan

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 99, any sex, with Scapular Dyskinesis or Athletic Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Scapular dyskinesis (SD) is common in overhead athletes and negatively influence the athletes' performance, increasing the risk of shoulder injury. The kinetic chain (KC) exercises for SD rehabilitation that emphasize importance of core strength and scapula stability during skillful performance. Ai Chi, the aquatic exercises performed in functional positions, which are adequate for power transfer of KC. This study will investigate the effect of KC-based water exercises, Ai Chi, on scapular muscles in overhead athletes with SD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Scapular Dyskinesis

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05714163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing